Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 49

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 49
---
180$(97,846)Weighted average common shares123,755,409120,066,972123,183,924119,461,485Effect of dilutive awards:Employee stock plans754,311—1,074,226—Diluted weighted-average common shares124,509,720120,066,972124,258,150119,461,485Diluted net income (loss) per share$0.28$(0.32)$0.00$(0.82)The following potential common shares were excluded from the calculation of diluted net income (loss) per share because their effect would have been anti-dilutive for the periods presented (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Stock options, restricted stock, and employee stock purchase plan3,332,653 5,411,904 3,404,257 5,411,904 Restricted stock units6,538,214 6,612,453 5,598,764 6,612,453 Shares committed under ESPP— 89,193 — 89,193 Total9,870,867 12,113,550 9,003,021 12,113,550 

9.    Subsequent Event

On August 7, 2025, the Company entered into a definitive agreement to acquire Scale Biosciences, Inc. for upfront cash and stock consideration of $30 million, plus contingent consideration that could become payable upon the achievement of certain milestones.

18

Table of Contents

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report and our audited consolidated financial statements and notes thereto and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on February 12, 2025 (our "Annual Report"). As discussed in the section titled “Special Note Regarding Forward-Looking Statements,” the following discussion and analysis, in addition to historical financial information, contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a